Table 1.
Subject characteristics by treatment status
| Characteristic | HAART, n = 21 | No HAART, n = 5 | P value |
|---|---|---|---|
| Male, n (%) | 15 (94) | 5 (100) | 0.8 |
| Female, n (%) | 1 (6) | 0 (0) | |
| Age years (mean) | 34 | 29 | 0.2 |
| Range | (25 to 53) | (23 to 35) | |
| Ethnicity | |||
| Asian | 2 (6%) | 0 (0%) | 0.1 |
| Caucasian | 14 (67%) | 4 (80%) | |
| Hispanic | 5 (24%) | 0 (0%) | |
| Pacific Islander | 0 (0%) | 1 (20%) | |
| HIV risk factor | |||
| Men sex with men | 19 (94%) | 5 (100%) | 0.6 |
| Heterosexual sex | 2 (6%) | 0 (0%) | |
| Stage of HIV at diagnosis | |||
| Preseroconversion | 4 (19%) | 0 (0%) | 0.3 |
| ≤30 days after seroconversion | 3 (14%) | 0 (0%) | |
| <6 months after seroconversion | 14 (67%) | 5 (100%) | |
| Initial treatment regimen | |||
| ZDV + 3TC + nelfinavir | 13 (62%)* | — | |
| ddI + d4T + nelfinavir + hydroxyurea | 4 (19%) | — | |
| ZDV + 3TC + indinavir | 1 (5%) | — | |
| 3TC + d4T + nevirapine | 1 (5%) | — | |
| d4T + 3TC + nelfinavir + hydroxyurea | 1 (5%) | — | |
| ZDV + 3TC + efavirenz | 1 (5%) | — |
Age (years), sex, race, HIV risk factors, stage of infection at diagnosis, and treatment, if any, are shown for HAART-treated and untreated individuals experiencing primary HIV infection. No statistically significant difference was observed between the treated and untreated groups. P values are for comparisons between the treated and untreated groups using Fisher's exact test for dichotomous categorical variables, chi square for categorical variables with more than two values, and Student's t test for continuous variables. n = number of individuals. ZDV, zidovudine; 3TC, lamivudine; ddI, didanosine; d4T, stavudine.
*
One of these subjects switched from ZDV to d4T after week 8.